ArticleCancer medicine2023
Survival and prognostic factors of early-stage non-small cell lung cancer in Central and Eastern Europe: A prospective cohort study.
Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Weight loss as a predictor of reduced survival in patients with lung cancer: a systematic review with meta-analysis.International journal of obesity (2005) · 2025Pooled it
- Adjuvant Chemotherapy with Traditional Chinese Herbal Granules Versus Placebo in Resected Non-Small Cell Lung Cancer: Updated Survival Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.Integrative cancer therapiesTrial
- Beyond the Scan: Adapting Multimodal Lung Cancer Screening for Central and Eastern Europe-Overcoming Systemic Barriers and Epidemiological Confounders.Medical sciences (Basel, Switzerland) · 2026Review
- Causal inference of glucocorticoid signaling in non-small cell lung cancer: integrating Mendelian randomization, single-cell transcriptomics, and imaging data.NPJ precision oncology · 2026Article
- Real-World Treatment and Outcomes in Resectable Early-Stage Non-Small Cell Cancer: THASSOS-INTL Australia Cohort.Aging medicine (Milton (N.S.W)) · 2026Article
- Prognostic Value of Systemic Inflammation Markers (NLR and Haemoglobin) in Non-Small Cell Lung Cancer: Survival Analysis from a Real-World Single-Centre Cohort Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Analysis of influencing factors of recurrence after thoracoscopic resection in patients with Stage I a lung adenocarcinoma.American journal of cancer research · 2026Article
- Integrated PET-IVIM-DKI MRI for predicting lymphovascular invasion in NSCLC.Insights into imaging · 2025Article
- Prognostic Factors and Survival Data of Stage I Lung Cancer: A Single-Center Experience.Journal of clinical practice and research · 2025Article
- Frequency and Characteristics of Craniomaxillofacial Tumors: A Five-Year Retrospective Institutional Study.Journal of clinical medicine · 2025Article
- Review
- Mesenchymal Stem Cell-Conditioned Media-Derived Exosomes Loaded WithFood science & nutrition · 2025Article
- Real-World Treatment Patterns and Associated Outcomes in Patients With Resectable Early-Stage Non-Small Cell Lung Cancer: The THASSOS International Study.Thoracic cancer · 2025Article
- EGFR-Targeted Therapies: A Literature Review.Journal of clinical medicine · 2024Review
- Prognostic value of circulating proteins at diagnosis among patients with lung cancer: a comprehensive analysis by smoking status.Translational lung cancer research · 2024Article
- Early-Stage Non-Small Cell Lung Cancer: Prevalence of Actionable Alterations in a Monocentric Consecutive Cohort.Cancers · 2024Article
- The Nine-Year Survival of Patients Operated for Non-Small-Cell Lung Carcinoma in a Tertiary Centre: The Impact of the Tumour Stage and Other Patient-Related Parameters.Medicina (Kaunas, Lithuania) · 2024Article
- Survival and prognostic factors of early-stage non-small cell lung cancer in Central and Eastern Europe: A prospective cohort study.Cancer medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 8 institutions in 6 countries.
Funding
Abstract
backgroundAlthough early diagnosis and surgical resection of the tumor have been shown to be the most important predictors of lung cancer survival, long-term survival for surgically-resected early-stage lung cancer remains poor.
aimsIn this prospective study we aimed to investigate the survival and prognostic factors of surgically-resected early-stage non-small cell lung cancer (NSCLC) in Central and Eastern Europe.
methodsWe recruited 2052 patients with stage I-IIIA NSCLC from 9 centers in Russia, Poland, Serbia, Czech Republic, and Romania, between 2007-2016 and followed them annually through 2020.
resultsDuring follow-up, there were 1121 deaths (including 730 cancer-specific deaths). Median survival time was 4.9 years, and the 5-year overall survival was 49.5%. In the multivariable model, mortality was increased among older individuals (HR for each 10-year increase: 1.31 [95% CI: 1.21-1.42]), males (HR:1.24 [1.04-1.49]), participants with significant weight loss (HR:1.25 [1.03-1.52]), current smokers (HR:1.30 [1.04-1.62]), alcohol drinkers (HR:1.22 [1.03-1.44]), and those with higher stage tumors (HR stage IIIA vs. I: 5.54 [4.10 - 7.48]). However, education, chronic obstructive pulmonary diseases (COPD), and tumor histology were not associated with risk of death. All baseline indicators of smoking and alcohol drinking showed a dose-dependent association with the risk of cancer-specific mortality. This included pack-years of cigarettes smoked (p-trend = 0.04), quantity of smoking (p-trend = 0.008), years of smoking (p-trend = 0.010), gram-days of alcohol drank (p-trend = 0.002), frequency of drinking (p-trend = 0.006), and years of drinking (p-trend = 0.016).
conclusionThis study shows that the 5-year survival rate of surgically-resected stage I-IIIA NSCLC is still around 50% in Central and Eastern Europe. In addition to non-modifiable prognostic factors, lifetime patterns of smoking and alcohol drinking affected the risk of death and disease progression in a dose-dependent manner in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.